Literature DB >> 16848088

Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas.

Ute Bartels1, Cynthia Hawkins, Ma Jing, Michael Ho, Peter Dirks, James Rutka, Derek Stephens, Eric Bouffet.   

Abstract

OBJECT: The authors' aim in conducting this study was to investigate retrospectively the prognostic significance of angiogenic features in optic pathway/hypothalamic gliomas (OPHGs) in children.
METHODS: Patients were identified in whom a diagnosis of OPHG was made using pathological analysis at the Toronto Hospital for Sick Children between 1985 and 2002. Tumor specimens were reviewed for diagnostic accuracy and adequacy of the specimen. Sections were immunostained with factor VIII to assess microvessel density (MVD). A ratio of alpha-smooth muscle actin to factor VIII immunostaining was calculated to arrive at a vascular maturity index (VMI). Vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) immunostaining were performed to evaluate angiogenic factors. In addition, the MIB-1 labeling index (LI) was used to assess proliferation. These factors were evaluated with respect to progression-free survival (PFS). Forty-one of 60 patients originally identified had adequate samples and follow up for inclusion in the study. Of these, eight patients had coexisting neurofibromatosis Type 1. Twenty-eight patients experienced tumor progression after the initial treatment (surgery with or without adjuvant treatment). Thirty-eight patients are still alive. A high MVD (> 21 vessels/1.2 mm2) was associated with a significantly higher rate of progression compared with a low MVD (< 21 vessels/1.2 mm2; p = 0.017). Microvessel density was also predictive of reduced PFS on multivariate analysis stratified for extent of resection (p = 0.04), and VMI as well as intensity and distribution of VEGF and VEGFR staining and the MIB-1 LI were not significantly associated with PFS.
CONCLUSIONS: These findings suggest that MVD is the best current predictor of PFS in incompletely resected OPHGs. This information highlights the importance of angiogenesis in regard to low-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16848088     DOI: 10.3171/ped.2006.104.5.314

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  23 in total

1.  Multiparameter computational modeling of tumor invasion.

Authors:  Elaine L Bearer; John S Lowengrub; Hermann B Frieboes; Yao-Li Chuang; Fang Jin; Steven M Wise; Mauro Ferrari; David B Agus; Vittorio Cristini
Journal:  Cancer Res       Date:  2009-04-14       Impact factor: 12.701

Review 2.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

3.  Bevacizumab in recurrent high-grade pediatric gliomas.

Authors:  Ashwatha Narayana; Saroj Kunnakkat; Jeena Chacko-Mathew; Sharon Gardner; Matthias Karajannis; Shahzad Raza; Jeffrey Wisoff; Howard Weiner; David Harter; Jeffrey Allen
Journal:  Neuro Oncol       Date:  2010-04-02       Impact factor: 12.300

4.  Expression and clinical significance of EGFL7 in malignant glioma.

Authors:  Chun-hai Huang; Xue-jun Li; Yi-zeng Zhou; Yong Luo; Cui Li; Xian-rui Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

5.  Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome.

Authors:  Linda R Margraf; Lynn Gargan; Yasmeen Butt; Nirupa Raghunathan; Daniel C Bowers
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

6.  Optic pathway gliomas in adolescence--time to challenge treatment choices?

Authors:  Amy Lee Chong; Jason D Pole; Katrin Scheinemann; Juliette Hukin; Uri Tabori; Annie Huang; Eric Bouffet; Ute Bartels
Journal:  Neuro Oncol       Date:  2013-01-07       Impact factor: 12.300

7.  Computer simulation of glioma growth and morphology.

Authors:  Hermann B Frieboes; John S Lowengrub; S Wise; X Zheng; Paul Macklin; Elaine L Bearer; Vittorio Cristini
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

8.  Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Michael J Fisher; Sarah S Milla; Kenneth J Cohen; Jeffrey H Wisoff; David H Harter; Judith D Goldberg; Tsivia Hochman; Amanda Merkelson; Michael C Bloom; Angela J Sievert; Adam C Resnick; Girish Dhall; David T W Jones; Andrey Korshunov; Stefan M Pfister; Charles G Eberhart; David Zagzag; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2014-05-06       Impact factor: 12.300

9.  Angiogenesis and angiogenic tyrosine kinase receptor expression in pediatric brain tumors.

Authors:  József Virág; István Kenessey; Christine Haberler; Violetta Piurkó; Katalin Bálint; Balázs Döme; József Tímár; Miklós Garami; Balázs Hegedűs
Journal:  Pathol Oncol Res       Date:  2013-11-05       Impact factor: 3.201

Review 10.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.